TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06783790
Drug: Avapritinib, azacitidine, Venetoclax
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A: Induction therapy period: After patients were screened and enrolled, they began to receive 1-2 cycles of induction therapy, and the specific administration regimen was as follows: Avapritinib 100mg po qd D1-D14, azacitidine 35mg/m2 ih D1-D5, Venetoclax 100mg po qd D1-D14. The 28-day cycle was followed by curative effect evaluation at the end of each cycle. Patients who achieved complete remission entered the consolidation treatment stage.~B: Consolidation therapy period: Patients who achieved complete remission after 1-2 cycles of induction therapy continued to receive avapritinib 100mg/d po. monotherapy for consolidation therapy, with a cycle of 28 days and a total of 4 cycles
Study: NCT06782490
Drug: BMS-986368
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04770896
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Study: NCT04770896
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
Study: NCT04770896
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
Study: NCT05783817
Drug: 3,4-Methyl enedioxy methamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.
Study: NCT05783817
Drug: Methamphetamine
Normalized name: Methamphetamine
DrugBank: Metamfetamine (DB01577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methamphetamine is a stimulant that affects the central nervous system. This is used as a control in the study.
Study: NCT06575296
Drug: Revumenib
Normalized name: Revumenib
DrugBank: Revumenib (DB18515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06322706
Drug: ABSK021
DrugBank: BSK02 (DB17434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABSK021 oral
Study: NCT06322706
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole oral
Study: NCT03651895
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The Drug was administered 500 mg twice daily for one week and increased to 1g twice daily for the reminder of the 3 months.
Study: NCT06584695
Drug: Transversus abdominis plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive transversus abdominis plane block with an oblique subcostal approach in the supine position. The anesthesiologist will place the linear ultrasound transducer obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus abdominis muscles along the subcostal line.
Study: NCT06584695
Drug: External Oblique Intercostal Plane Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive external oblique intercostal block the patient will be in the supine position with their ipsilateral arm abducted, A linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, with the orientation marker directed cranially. The skin will be sterilized, and the probe will be placed over the sixth rib medial to the anterior axillary line in a parasagittal orientation the in-plane technique with a 22G, 80 mm block needle will be used to inject 25 ml of 0.25% bupivacaine into the external oblique intercostal plane.
Study: NCT04718415
Drug: sintilimab, paclitaxel, carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT06792214
Drug: Nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paxlovid PO BID for 5 days + standard of care
Study: NCT06792214
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Veklury IV daily for 5 days + standard of care
Study: NCT04524390
Drug: Maralixibat
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small molecule inhibitor of the ileal bile acid transporter (IBAT)
Study: NCT06605599
Drug: ABBV-932
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06633536
Drug: Ravulizumab
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: open-label arm with ravulizumab administrated within the scope of routine clinical practice
Study: NCT05489705
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per product label
Study: NCT05489705
Drug: Non-mavacamten symptomatic oHCM therapy
Normalized name: Mavacamten
DrugBank: AVAC (DB05441)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
Study: NCT05147805
Drug: Treprostinil Palmitil
Normalized name: Treprostinil palmitil
DrugBank: Treprostinil palmitil (DB18792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
Study: NCT05374512
Drug: Dato-DXd
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug. Provided in 100mg vials. IV infusion.
Study: NCT05374512
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Infusion. Active comparator
Study: NCT05374512
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion. Active comparator
Study: NCT05374512
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion. Active comparator
Study: NCT05374512
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion. Active comparator
Study: NCT04617314
Drug: RC108
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
Study: NCT06014775
Drug: Anti-CD38 antibody Injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Study: NCT05281510
Drug: Vesatolimod
Normalized name: Vesatolimod
DrugBank: Vesatolimod (DB12687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06062810
Drug: Crizotinib - Usual
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * XALKORI - crizotinib capsule (high dose)~* XALKORI 250 mg taken orally twice daily
Study: NCT06062810
Drug: Crizotinib - Study
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * XALKORI - crizotinib capsule (low dose)~* XALKORI 200 mg taken orally twice daily
Study: NCT06477055
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib, 80mg, po, qd.
Study: NCT06650709
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.
Study: NCT06650709
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).
Study: NCT06650709
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
Study: NCT05653492
Drug: Sulforaphane
Normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing study one to four 30 mg/d tablets depending on weight
Study: NCT04989803
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy administered intravenously
Study: NCT06149559
Drug: rozanolixizumab
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rozanolixizumab solution for injection
Study: NCT06283667
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
Study: NCT05714553
Drug: Fosifloxuridine Nafalbenamide
Normalized name: Fosifloxuridine nafalbenamide
DrugBank: Fosifloxuridine nafalbenamide (DB14859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05714553
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT05714553
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06591390
Drug: Ticagrelor 90 MG
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Study: NCT06591390
Drug: Cilostazol 100 MG
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study: NCT06548607
Drug: RD06-04 or RD06-05 CART Cell Injection
Normalized name: edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study: NCT04570423
Drug: Eflapegrastim
Normalized name: Eflapegrastim
DrugBank: Eflapegrastim (DB15001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
Study: NCT05419505
Drug: Antifibrinolytic Agent
Normalized name: ANTIFIBRINOLYTICS
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered by participants enrolled in Cohort 7.
Study: NCT05155345
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
Study: NCT05155345
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
Study: NCT06067828
Drug: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
Study: NCT06067828
Drug: Treatment B: Budesonide and Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
Study: NCT05910554
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to metformin will be assigned the active arm.
Study: NCT05910554
Drug: Cellulose
Normalized name: Cellulose
DrugBank: Sodium cellulose phosphate (DB06776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to cellulose will be assigned the placebo arm.
Study: NCT05236582
Drug: Herombopag
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
Study: NCT04718376
Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study: NCT06772753
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active comparator for psychedelic effects
Study: NCT06772753
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: psychoactive substance
Study: NCT06772753
Drug: Dextromethorphan (DXM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: psychoactive substance
Study: NCT06772753
Drug: Dimethyltryptamine (DMT)
Normalized name: Dimethyltryptamine
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: psychoactive substance
Study: NCT06772753
Drug: Methylenedioxymethamphetamine (MDMA)
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: psychoactive substance
Study: NCT06772753
Drug: Tetrahydrocannabinol (THC)
Normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: psychoactive substance
Study: NCT05874154
Drug: Botulinum toxin injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
Study: NCT05729282
Drug: Diazoxide oral suspension, 1 mg per kg per dose
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
Study: NCT05729282
Drug: Diazoxide oral suspension, 2 mg per kg per dose
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
Study: NCT05729282
Drug: Deuterated water (2H2O/D2O)
Normalized name: Deuterated water
DrugBank: Deuterium oxide (DB19251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
Study: NCT04272242
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04272242
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04272242
Drug: Rifapentine (RPT)
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06589921
Drug: Pirfenidone Modified-Release Tablets
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: take the tablet under fed condition, 1 tablet at a time, once a day.
Study: NCT06589921
Drug: Pirfenidone Tablets
Normalized name: Pirfenidone Tablets
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ake the tablet under fed condition, 1 tablet at a time, three times a day.
Study: NCT04721626
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)
Study: NCT04721626
Drug: Povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine.
Study: NCT06455826
Drug: VP-001
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy
Study: NCT06594016
Drug: Fosigotifator
Normalized name: Fosigotifator
DrugBank: Fosigotifator (DB19409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06604611
Drug: Colchicine 0.5 MG Oral Tablet Once Daily
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
Study: NCT04625946
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout.
Study: NCT04467983
Drug: Denosumab Injection
Normalized name: denosumab Injection
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
Study: NCT04467983
Drug: Abaloparatide
Normalized name: Abaloparatide
DrugBank: Abaloparatide (DB05084)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.